Literature DB >> 24349622

At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death.

Yuichi Masuda1, Hirohito Ichii1, Nosratola D Vaziri1.   

Abstract

BACK GROUND: Overt and subtle iron overload cause diabetes by lowering insulin production and promoting insulin resistance. Via divalent metal transporters pancreatic beta cells take up non-transferrin-bound iron which by catalyzing Fenton reaction can cause oxidative stress. Due to their strict dependence on mitochondrial glucose metabolism and limited antioxidant capacity, beta cells are exquisitely vulnerable to oxidative stress and hence catalytically active iron. Intravenous (IV) iron preparations are routinely used in the management of anemia in patients with end stage renal disease. This has led to an epidemic of iron overload in this population. This study explored the effect of pharmacologically-relevant concentrations of a commonly used IV iron preparation on the beta cells in isolated pancreatic islets.
METHODS: Isolated rat pancreatic islets were incubated for 24 hours in culture media containing vehicle or pharmacologically-relevant concentration of ferric sucrose and examined for the extent of cell death and oxidative stress.
RESULTS: Exposure to iron sucrose resulted in a concentration-dependent oxidative stress and pancreatic islet cell death predominantly affecting beta cells.
CONCLUSIONS: At pharmacologically-relevant concentrations a commonly used IV iron preparation causes oxidative stress and beta cell death. These findings suggest that indiscriminate use of IV iron may impair insulin production capacity in ESRD patients the majority of whom have Type-2 diabetes.

Entities:  

Keywords:  Diabetes; anemia; cardiovascular disease; chronic kidney disease; glucose metabolism; hemodialysis; insulin; metabolic syndrome

Year:  2013        PMID: 24349622      PMCID: PMC3853425     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  40 in total

1.  Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes.

Authors:  Hirohito Ichii; Yuichi Masuda; Tania Hassanzadeh; Mateen Saffarian; Sastry Gollapudi; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2012-06-19       Impact factor: 3.754

2.  Prevalence of body iron excess in the metabolic syndrome.

Authors:  Claudia Bozzini; Domenico Girelli; Oliviero Olivieri; Nicola Martinelli; Antonella Bassi; Giovanna De Matteis; Ilaria Tenuti; Valentina Lotto; Simonetta Friso; Francesca Pizzolo; Roberto Corrocher
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

Review 3.  Clinical aspects of iron use in the anemia of kidney disease.

Authors:  Walter H Hörl
Journal:  J Am Soc Nephrol       Date:  2007-01-17       Impact factor: 10.121

4.  Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease.

Authors:  Paolo Ferrari; Hemant Kulkarni; Shyam Dheda; Susanne Betti; Colin Harrison; Timothy G St Pierre; John K Olynyk
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

5.  Protective effect of persimmon (Diospyros kaki) peel proanthocyanidin against oxidative damage under H2O2-induced cellular senescence.

Authors:  Young A Lee; Eun Ju Cho; Takako Yokozawa
Journal:  Biol Pharm Bull       Date:  2008-06       Impact factor: 2.233

6.  Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation.

Authors:  Nosratola D Vaziri
Journal:  Am J Med       Date:  2012-07-13       Impact factor: 4.965

7.  Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration.

Authors:  Vaijinath S Kamanna; Shobha H Ganji; Stanislav Shelkovnikov; Keith Norris; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2011-12-29       Impact factor: 3.754

8.  The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure.

Authors:  Chun Soo Lim; Nosratola D Vaziri
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

9.  Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival.

Authors:  Ajay Gupta; Jiaying Zhuo; Junli Zha; Srinivasa Reddy; Jonathan Olp; Amy Pai
Journal:  BMC Nephrol       Date:  2010-08-17       Impact factor: 2.388

10.  Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications.

Authors:  M Qian; M Liu; J W Eaton
Journal:  Biochem Biophys Res Commun       Date:  1998-09-18       Impact factor: 3.575

View more
  7 in total

Review 1.  The utility of iron chelators in the management of inflammatory disorders.

Authors:  C Lehmann; S Islam; S Jarosch; J Zhou; D Hoskin; A Greenshields; N Al-Banna; N Sharawy; A Sczcesniak; M Kelly; K Wafa; W Cheliak; B Holbein
Journal:  Mediators Inflamm       Date:  2015-03-23       Impact factor: 4.711

2.  Severity of Anemia Predicts Hospital Length of Stay but Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study.

Authors:  Katherine Garlo; Deanna Williams; Lee Lucas; Rocket Wong; Joel Botler; Stuart Abramson; Mark G Parker
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

3.  Prediabetes, elevated iron and all-cause mortality: a cohort study.

Authors:  Arch G Mainous; Rebecca J Tanner; Thomas D Coates; Richard Baker
Journal:  BMJ Open       Date:  2014-12-11       Impact factor: 2.692

Review 4.  Safety concerns about intravenous iron therapy in patients with chronic kidney disease.

Authors:  Lucia Del Vecchio; Selena Longhi; Francesco Locatelli
Journal:  Clin Kidney J       Date:  2016-01-06

5.  Acute Effects of Blood Transfusion on Insulin Sensitivity and Pancreatic β-Cell Function in Children with β-Thalassemia/Hemoglobin E Disease.

Authors:  Somboon Wankanit; Ampaiwan Chuansumrit; Preamrudee Poomthavorn; Patcharin Khlairit; Sarunyu Pongratanakul; Pat Mahachoklertwattana
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-07-24

Review 6.  Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.

Authors:  Guy Rostoker; Nosratola D Vaziri; Steven Fishbane
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 7.  Regulatory Connections between Iron and Glucose Metabolism.

Authors:  Carine Fillebeen; Nhat Hung Lam; Samantha Chow; Amy Botta; Gary Sweeney; Kostas Pantopoulos
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.